Sуть
Starting from a recent Wednesday, Medicare launched the GLP-1 Bridge program, allowing eligible beneficiaries to access popular weight loss medications for just $50 a month. This initiative aims to provide financial relief for older Americans struggling with obesity while gathering data for potential long-term coverage of GLP-1 drugs.
Как это работало
To qualify for the program, beneficiaries must have Medicare drug coverage and meet specific BMI criteria: a BMI of 35 or higher, or a BMI of 27 or higher with an associated health condition like prediabetes or a history of heart attack. A prescription for a covered GLP-1 drug must be obtained through a healthcare provider, who will also fill out a prior authorization form. Covered medications include Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy, all FDA-approved for weight loss.
Результат
With over 70 million Americans enrolled in Medicare, at least 10 million are overweight or obese. However, the actual number of beneficiaries who will benefit from this program remains uncertain. The program is set to run until December 31, 2027, but participants must note that their payments won't count towards insurance deductibles. Early feedback indicates the program could dramatically improve lives, as seen in cases like Gloria Dralla, who lost 40 pounds thanks to Wegovy.
Why It Matters для тебя
If you or someone you know is struggling with weight loss and is a Medicare beneficiary, it’s crucial to check eligibility for the GLP-1 Bridge program. Understanding the criteria can open up affordable treatment options and potentially lead to significant health improvements. Contact your healthcare provider to explore this opportunity and take the first step towards managing weight effectively.
